ReviewAdvances in experimental medicine and biology
The Metabolism of Renal Cell Carcinomas and Liver Cancer.
Review in Advances in experimental medicine and biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A Deep Insight Into Regulatory T Cell Metabolism in Renal Disease: Facts and Perspectives.Frontiers in immunology · 2022Review
- Mitochondrial uncoupling and the disruption of the metabolic network in hepatocellular carcinoma.Oncotarget · 2020Article
- The Metabolic Interplay between Cancer and Other Diseases.Trends in cancer · 2019Review
- Drugging cancer metabolism: Expectations vs. reality.International review of cell and molecular biology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
key pointsAccording to data from the American Cancer Society, cancer is one of the deadliest health problems globally. Annually, renal cell carcinoma (RCC) and liver cancer cause more than 100,000 and 800,000 deaths worldwide, respectively [1–4], creating an urgent need to develop effective therapeutic treatments to increase patient survival outcomes. New therapeutic treatments are expected to address a major factor contributing to cancer’s resistance to standard therapies: oncogenic heterogeneity. Because gene expression can vary tremendously among different types of cancers, different patients of the same tumor type, and even within individual tumors, various metabolic phenotypes can emerge, making single-therapy approaches insufficient. This heterogeneity translates into changes in the landscape of metabolic enzymes and biomolecules within both the cancer cell and tumor microenvironment. Novel strategies targeting the diverse metabolism of cancers aim to overcome this obstacle, and though some have yielded positive results, it remains a challenge to uncover all of the distinct metabolic profiles of RCC and liver cancer. Nonetheless, the metabolic-oriented research focusing on these cancers has offered different, fresh new perspectives, which are expected to contribute heavily to the development of new therapeutic treatments.
Indexed as
Identifiers
29946779What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.